Atorvastatin
A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.
Masse moléculaire
558,6400 g/mol
LogP
5,00
TPSA
112,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Classes de médicaments
Mécanisme d'action
Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitive inhibitor of HMG-CoA reductase.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
Molecular Formula
C33H35FN2O5
HBD / HBA
4 / 6
Liaisons Rotatives
12
Atomes Lourds
41
Cyclosporine dramatically increases atorvastatin plasma levels through combined inhibition of CYP3A4, OATP1B1, and P-gp, substantially raising the risk of myopathy and rhabdomyolysis.
Doxycycline may slightly raise atorvastatin plasma levels through weak inhibition of CYP3A4 and P-glycoprotein, though clinically significant myopathy from this combination is rarely reported.
Diltiazem inhibits CYP3A4-mediated atorvastatin metabolism, increasing atorvastatin plasma concentrations and the risk of myopathy and rhabdomyolysis.
Amlodipine weakly inhibits CYP3A4-mediated atorvastatin metabolism, leading to a modest increase in atorvastatin exposure; the combination is generally used safely in clinical practice.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.
Competitive inhibitor of HMG-CoA reductase.
Key pharmacokinetic parameters for Atorvastatin: Half-life: 14 hours.
Yes, Atorvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1487. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60823. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="atorvastatin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/atorvastatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/atorvastatin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/atorvastatin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="atorvastatin"></drugfyi-drug>